John Vandermosten

@azitrainc's co-founder & Chief Operating Officer, Travis Whitfill, outlines the pathway forward for a cosmeceutical in contrast to a pharmaceutical product. $AZTR #Cosmeceuticals #SkinBarrier #Filaggrin #Dermatology #SkincareScience #SkinMicrobiome youtube.com/shorts/NQHPISI…

CEO Shane Schaffer outlines Cingulate's product launch strategy with partners Indegene and IQVIA. $CING #PrecisionTimedRelease #NASDAQ #Biotech #BioPharma #FDA youtube.com/shorts/_TlzCIv…

@RNAoncology's CEO Philippe Calais gives a brief synopsis of what $RNAZ offers stakeholders. #RNATherapeutics #miRNA #TTX-MC138 #OligonucleotideTherapy #PrecisionOncology youtube.com/shorts/DYF2mkJ…

@Spectral_MDAI appoints Darcy Bajko as Chief Commercial Officer *Will head $MDAI global launch of DeepView burn *Previously @ Integra LifeSciences, Smith + Nephew & MediView XR where she launched 3 imaging platforms finance.yahoo.com/healthcare/art…

Azitra's co-founder & Chief Operating Officer, Travis Whitfill, introduces the cosmeceuticals program. youtube.com/shorts/w2jFZMW… $AZTR #Cosmeceuticals #SkinBarrier #Filaggrin #Dermatology #SkincareScience #SkinMicrobiome

@BioLineRx_Ltd announces GLIX1 data *Preclinical *Ovarian cancer *Demonstrates synergy between GLIX1 & PARPi in patient-derived xenograft model $BLRX ir.biolinerx.com/news-releases/…

CEO Shane Schaffer reviews @CingulateInc's market access and precommercialization activities. $CING is speaking to PBMs, health plans and government payors among others with a focus on accessibility. youtube.com/shorts/GYXWQq9… #PrecisionTimedRelease #NASDAQ #Biotech #BioPharma #FDA

After BIO, Lexaria reports biz development meetings with a diverse group of companies. $LEXX is seeking partners to advance DehydraTECH, particularly in GLP-1s. "Not a week goes by without discussion" Seeing renewed interest in CBD & nicotine. lexariabioscience.com/2026/07/06/lex…

@RNAoncology's Chief Scientific Officer & Co-Founder Dr. Zdravka Medarova outlines the competitive environment in RNA therapeutics. youtube.com/shorts/M_tuVu-… $RNAZ #RNATherapeutics #miRNA #TTXMC138 #OligonucleotideTherapy #precisiononcology

@Cingulate CEO Shane Schaffer runs through team accomplishments for precommercialization efforts in manufacturing, medical affairs & fielding account managers. $CING #PrecisionTimedRelease #NASDAQ #Biotech #BioPharma #FDA youtube.com/shorts/iJictII…

@CingulateInc CEO Shane Schaffer explains why CTx-1301 is a differentiated product in the market that addresses an unmet need and provides entire active day efficacy. youtube.com/shorts/ZeWP90-… $CING #PrecisionTimedRelease #NASDAQ #Biotech #BioPharma #FDA

TransCode Therapeutics' Chief Scientific Officer & Co-Founder Dr Zdravka Medarova explains how targets are identified & drugs designed for RNA therapeutics. youtube.com/shorts/mHWe7q3… $RNAZ #RNATherapeutics #miRNA #TTXMC138 #OligonucleotideTherapy #PrecisionOncology

Cingulate added to Russell 3000. Expect positive volume impact as index funds pick up shares. $CING cingulate.com/news-releases/… See CEO Schaffer point out CTx-1301 advantages: youtube.com/shorts/6_BzqGy…

CEO Shane Schaffer points out the advantages of @CingulateInc's ADHD treatment: CTx-1301. youtube.com/shorts/6_BzqGy… $CING #PrecisionTimedRelease #NASDAQ #Biotech #BioPharma #FDA

TransCode Therapeutics' Chief Scientific Officer Dr. Zdravka Medarova explains RNA Therapeutics along with its important applications & capabilities. $RNAZ youtube.com/shorts/DbTlU78… #RNATherapeutics #miRNA #TTX #OligonucleotideTherapy #PrecisionOncology

The Japan Patent Office allows @DyadicInc's claims for C1 & Dapibus. Partner Intralink will help $DYAI develop business here with COO Hazelton conducting meetings. dyadic.com/dyadic-expands…

@achievelifesci joins Russell 2000 index on 26Jun. Expect positive pressure as index funds rebalance. $ACHV achievelifesciences.com/achieve-joins-…

CEO Shane Schaffer explains Cingulate Inc.'s position in the label development process with the #FDA. Clinical and safety data is already known via Focalin XR. $CING will add its studies to the base. #PrecisionTimedRelease #PTR #NASDAQ #Biotech #BioPharma #FDAApproval youtube.com/shorts/pqjxqy9…

@CingulateInc CEO Shane Schaffer explains the FDA’s information requests & other highlights from the CTx-1301 Complete Response Letter. youtube.com/shorts/DdxRmff… $CING #PrecisionTimedRelease #PTR #NASDAQ #Biotech #BioPharma #FDA #PDUFA #NDA #DrugDelivery #ExtendedRelease #ControlledRelease

@Ligand_LGND closes 0% coupon convert *$700mm raised, $678 net *Call spread limits dilution *$334 conversion price *2031 maturity $LGND investor.ligand.com/news-and-event…